Lung cancer

RMC-LUNG-101

Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors

Open at Paris since : 31/07/2024
Target : Adult
Phase : Phase I/II

Trial description

To evaluate the safety and tolerability of RMC-6291 in combination with pembrolizumab, with or without chemotherapy, in patients with advanced KRASG12C-mutated solid tumors;À To define the RP2DS for RMC-6291 in combination with pembrolizumab, with or without chemotherapy, in patients with advanced KRASG12C-mutated solid tumors.

Url of the trial

Main investigator

PAULINE DU RUSQUEC

Médecin

Contact